Emma Chaffin’s Post

The Inflation Reduction Act of 2022 (P.L. 117-169), signed into law August 2022 by President Biden. This new law makes improvements to Medicare - expanding benefits, lowering drug costs, and improving program stability. What we can expect to see from these drug price negotiation programs: - Drug price negotiation will advance health equity, as millions of consumers will be able to purchase their medications at more affordable prices. - Greatest relief expected to affect lower-income Medicare beneficiaries - Benefits of negotiations will grow over the years: (x10) Part D for 2026 & 2027, up to (x15) for Part B and D for 2028, up to (x20) for Part B and D for each year following Topics to bring into discussion: - Can we expect to see a decrease in free drug programs? Copay assistance? - How will this affect margins for Part B drugs administered in-office? #medicare #patientaccess #affordablehealthcare https://lnkd.in/ema4C6YQ

Medicare drug price negotiation is benefitting you. Look at the savings in your home state: https://lnkd.in/g7z3dcHQ

‼️ Today’s the day! 💊@CMSgov begins the first-ever price negotiations for high-cost drugs in Medicare 👍Thanks to the Inflation Reduction Act – these negotiations will lower soaring Rx prices and help more patients afford their medicines https://lnkd.in/ehjgE-be 

While we are still only in the early stages of the first negotiations between manufacturers and CMS, there is already talk of potentially expanding the number of eligible drugs for negotiation. See our latest thoughts on the Inflation Reduction Act here.

More timely info from Nyah Phengsitthy! CMS Hails Receipt of Counteroffers, Pledges Its “Good Faith” The critical language is here: CMS promises “constructive dialogue and [is] glad the drug companies are coming to the table….These are good-faith, up front negotiations.” The messaging is clearly designed for consumption in the court of public opinion —and as an adjunct to the government’s litigation strategy. All those procedural defenses we see the government asserting in the drug maker lawsuits are designed to buy time for the “negotiations” to proceed. The underlying analysis is that it becomes harder for the courts to intervene once the “savings” have become concrete. Soothing words about “good faith” are intended to help build the case for enough space for the “negotiations” to reach a point where their fulfillment becomes a foregone conclusion. #drugdevelopment #drugpricing #raredisease #patientsfirst #medicare

Few domestic political decisions have a substantial impact on the future of our country. The Biden Administration's decision to move forward with Medicare drug pricing negotiations is one of them. This is a decision that the previous administration also supported. Learn more about the U.S.'s negotiation over drug pricing here: https://lnkd.in/ezpBHMP9

Talked to HHS Secretary Xavier Becerra for my latest story—all 10 drugmakers with drugs selected for the Medicare Drug Price Negotiation Program have agreed to participate. That means the negotiation process can now begin, Becerra told me. The program, which was created under the 2022 Inflation Reduction Act,  is intended to lower the cost of some of the most popular and expensive drugs in Medicare. Read more: #medicare #drugprices #HHS #drugpricenegotiation

https://lnkd.in/gyUCR2xx Stay informed: https://lnkd.in/g8VEd6bW   This price negotiation will provide much needed relief to Americans who are struggling to afford their medications. #MedicareNegotiations #BidenAdministration #PharmaceuticalCompanies

One of the many objectives of the Inflation Reduction Act is to lower prescription drug costs and increase access to life-saving medications. But defining access continues to be a challenge. In preparation for drug negotiations with Medicare, today Centers for Medicare & Medicaid Services held the first of many listening sessions with patients and patient advocates. The goal being to provide patients with a venue for Medicare to understand patient's daily life dealing with their conditions and their thoughts on the value of therapeutic alternatives. I had the opportunity to listen to today’s opening session with CMS for apixaban/Eliquis, one of the ten drugs selected for negotiation for 2026. Unsurprisingly, one of the key themes from today’s speakers were their issues and concerns over continued access to their medications and the healthcare system in general. Concerns over formulary management becoming more demanding, confusion on financial assistance, issues with preferred pharmacy networks, worries over access in rural communities, and issues with basic enrollment in health plans. I commend the CMS for this first of many sessions to better define the situation at hand. However, we must recognize that these listening sessions are only continuing to bring to light the challenges that patients have accessing healthcare. #marketaccess #patientaccess #inflationreductionact #medicare #formulary

Following CMS's announcement of the first 10 drugs targeted for #Medicare price negotiations, #AvalereExpert Kelsey Lang spoke with MedPage Today about what is behind discrepancies between experts' list predictions and the published list: https://lnkd.in/ejbRZnHT Read more about Kelsey and other #IRA implementation experts' take on the announcement here: https://lnkd.in/ePp3TqeN #drugpricing #InflationReductionAct